Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | MLH1 |
Variant | I68N |
Impact List | missense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | MLH1 I68N lies within the ATPase domain of the Mlh1 protein (PMID: 22753075). I68N results in decreased mismatch repair (MMR) activity in in vitro assays (PMID: 17510385, PMID: 15475387), loss of interaction with Pms2 and Exo1 in yeast two-hybrid assays, and loss of repression activity in a yeast reporter assay (PMID: 12810663), and therefore, is predicted to lead to a loss of Mlh1 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
MLH1 mutant MLH1 inact mut MLH1 I68N |
Transcript | NM_000249.4 |
gDNA | chr3:g.36996705T>A |
cDNA | c.203T>A |
Protein | p.I68N |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001258271.2 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
XM_005265161.2 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001258271.1 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_000249.3 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001354630.1 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001354628.2 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001354629.1 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001354628.1 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
XM_005265161.3 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_000249.4 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001354629.2 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
NM_001354630.2 | chr3:g.36996705T>A | c.203T>A | p.I68N | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|